Table 1. Demographic and clinical characteristics of study cohort.
| SLE Patients | Control Subjects | p | |||
|---|---|---|---|---|---|
| N = 73 | N = 34 | ||||
| African-Americans [N (%)] | 47 (64.4) | 22 (64.7) | 0.97 | ||
| Atherosclerosis [N (%)] | 38 (52.1) | 21 (61.8) | 0.35 | ||
| African-Americans with Atherosclerosis) [N (%)] | 30 (63.8) | 12 (54.5) | |||
| Age (years) [mean ± SD] | 42.11± 14.2 | N = 33 | 36.1 ±13.9 | 0.045 | |
| SLEDAI total [median (IQR)] | 2 (4.0) | ||||
| # ACR criteria [median (IQR)] | 6 (3.0) | ||||
| Lupus nephritis [N (%)] | 11 (15.1) | ||||
| Patients on Prednisolone [N (%)] | 39 (53.4) | ||||
| Patients on immune-suppressants [N (%)] | |||||
| MMF | 25 (34.2) | ||||
| CYC | 10 (13.7) | ||||
| AZA | 20 (27.4) | ||||
| MTX | 10 (13.7) | ||||
| Patients on anti-malarials (HCQ) [N (%)] | 37 (50.7) | ||||
| Patients on biologics (RTX) [N (%)] | 5 (6.8) | ||||
| Serum creatinine (mg) [mean ± SD] | N = 67 | 1.2 ± 1.4 | |||
| Albumin (g/L) [mean ± SD] | N = 64 | 3.5 ± 0.6 | |||
| Cholesterol (mM) [mean ± SD] | N = 42 | 181.3 ± 48.4 | N = 10 | 201.4 ± 37.7 | 0.023 |
| LDL (mM) [mean ± SD] | N = 42 | 102.6 ± 40.4 | N = 10 | 128.8 ± 41.0 | 0.07 |
| HDL (mM) [mean ± SD] | N = 42 | 54.9 ± 16.7 | N = 10 | 51.4 ± 11.5 | 0.54 |
| TG (mM) [mean ± SD] | N = 42 | 124.0 ± 58.6 | N = 10 | 126.8 ± 100.2 | 0.93 |
Italicized bold numbers indicate p < 0.05
Abbreviations: SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ACR, American College of Rheumatology score; MMF, mycofenolate; CYC, cyclophosphamide; AZA, azathioprine; MTX, methotrexate; HCQ, hydropxychloroquine; RTX, rituximab; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides